Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Extracellular Vesicles 2017

Niek Dekker's Biography



Niek Dekker, Associate Director, Discovery Biology, AstraZeneca

1991: PhD in enzymology, Utrecht University, the Netherlands
1994-2000: Assistant Professor Utrecht University, the Netherlands.
2000-2004: Team Leader Protein Engineering, Structural Chemistry Laboratorie, AstraZeneca, Sweden.
2004-2008: Associate Director Protein Engineering Section, Structural Chemistry Laboratories, AstraZeneca, Sweden
2008-2012: Delivery Leader to central nervous system and pain (CNS&P) iMed, Cell, Protein & Structural Sciences, Discovery Enabling Capabilities and Sciences, AstraZeneca, Sweden
2012-2017: Principal scientist in Reagents & Assay Development, Discovery Sciences, AstraZeneca, Sweden
2017-present: Associate Director biochemical assay development, Discovery Biology, AstraZeneca, Sweden

Niek Dekker Image

Engineered Extracellular Vesicles For CRISPR Gene Editing

Wednesday, 27 September 2017 at 11:30

Add to Calendar ▼2017-09-27 11:30:002017-09-27 12:30:00Europe/LondonEngineered Extracellular Vesicles For CRISPR Gene EditingExtracellular Vesicles 2017 in Cripps Court, Magdalene College, Cambridge, UKCripps Court, Magdalene College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com

Exosomes present an exciting opportunity as biological delivery vehicle of therapeutic cargo with excellent safety, low intrinsic immunogenicity, cell-specific tropism and biological delivery efficacy. Application of CRISPR/Cas9 requires the functional delivery of the ribonucleoprotein (RNP) complex of Cas9 and guide RNA. Engineering of the production cell lines can be used to introduce cargo into the exosomes, and examples for the introduction of fluorescent and luminescent proteins in exosomes will be disclosed. Uptake in recipient cells can be monitored using high content imaging to provide insight in kinetics and localization. Functional delivery can be analyzed using several assays for the gene editing event (e.g., Cel1 and TIDE). Use of exosomes for delivery of CRISPR/Cas9 has applications for ex vivo manipulation of primary cells (e.g., T cells) and in vivo editing of genes in diseased tissue.


Add to Calendar ▼2017-09-26 00:00:002017-09-28 00:00:00Europe/LondonExtracellular Vesicles 2017Extracellular Vesicles 2017 in Cripps Court, Magdalene College, Cambridge, UKCripps Court, Magdalene College, Cambridge, UKSELECTBIOenquiries@selectbiosciences.com